By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Zealand Pharma A/S  

Smedeland 26 B

Glostrup    DK-2600  Denmark
Phone: 45-43-28-12-00 Fax: 45-43-28-12-12


Company News
Zealand Pharma  (ZEAL.CO) Clarifies Its Role In U.S. Patent Litigation Relating To Lixisenatide And Confirms Its Confidence In A Strong Patent Status For The Product 2/5/2016 7:28:02 AM
Sanofi (SNY) Pays $20 Million Milestone and Redeems Priority Review Voucher for Zealand Pharma  (ZEAL.CO)’s LixiLan 12/23/2015 6:41:28 AM
Zealand Pharma  (ZEAL.CO) Is Ready To Take Next Steps In A Diligent Growth Strategy For Accelerated Value Creation: From Peptide To Patient 11/4/2015 8:19:15 AM
Zealand Pharma  (ZEAL.CO) Reports Lyxumia Royalty Revenue For Q3 2015 And That Sanofi (SNY) Confirms Expected Next Steps In The U.S. Regulatory Process 10/29/2015 10:46:09 AM
Zealand Pharma  (ZEAL.CO) Meets Development Milestone In Collaboration With Boehringer Ingelheim 10/9/2015 7:12:45 AM
Zealand Pharma  (ZEAL.CO) Release: Major Shareholder Announcement 7/30/2015 7:01:33 AM
Zealand Pharma  (ZEAL.CO) Release: Major Shareholder Announcement 6/15/2015 8:49:10 AM
Zealand Pharma  (ZEAL.CO) Informs Of Updates Given By Sanofi (SAN.PA) On Lyxumia And Lixilan On An IR Thematic Conference Call On Diabetes 6/9/2015 10:38:33 AM
Zealand Pharma  (ZEAL.CO) Informs That Data Presented From The ELIXA Study Establish Lyxumia As The First GLP-1 Receptor Agonist With Cardiovascular Safety Proven In A Long-Term Outcome Trial 6/9/2015 8:52:34 AM
Presentations On Two Novel Zealand Pharma  (ZEAL.CO) Preclinical Peptide Therapeutics As Possible Approaches For The Treatment Of Type 2 Diabetes And Obesity At The American Diabetes Association's 74th Scientific Sessions 6/8/2015 7:31:15 AM